Introduction: Natural polyphenolics are frequently inefficient in metabolic disorders due to multi-target promiscuity and restrictive in vivo bioavailability. This study proposes a chemoinformatics framework utilizing human bioactivity data to map micro-structural variations of privileged scaffolds to macro-systemic network perturbations, establishing a baseline for biomarker-guided supplement formulation.
Methods: Human screening assays for quercetin, resveratrol, and five elite analogues (kaempferol, myricetin, fisetin, piceatannol, pterostilbene) were extracted from the ChEMBL database. Over 1,400 entries were filtered through an in silico pharmacokinetic constraint (pChEMBL = 6.0) to construct empirical Structure-Activity Relationship (SAR) matrices and a bipartite compound-target-extended disease network resolving an additional 190 unique protein nodes.
Results: Flavonoid B-ring hydroxylation strictly governed target selectivity: monohydroxylation (kaempferol) optimized dipeptidyl peptidase 4 binding (DPP-4, Max pChEMBL = 6.31), whereas a di-hydroxylated catechol motif (quercetin) maximized aldo-keto reductase 1B1 potency (Max pChEMBL = 7.83). Transitions to methoxylated stilbenes (pterostilbene) maximized target occupancy within the hydrophobic catalytic domain of protein deacetylase HDAC6 (Max pChEMBL = 6.26), while low-steric, reduced-hydroxylation patterns (kaempferol) favored Casein kinase 2 (Max pChEMBL = 6.68).
Conclusions: These findings reconcile previous monoamine oxidase (MAO-A/B) molecular docking leads by contextualizing lower-affinity hubs within a broader polypharmacological network. These empirical SAR observations provide a systems-level knowledge base suitable for adaptive decision-support systems designed to personalize phytochemical combinations dynamically based on metabolic markers like Glycated Hemoglobin (HbA1c).